The presentation discusses various endpoints in aortic valve development and Transcatheter Aortic Valve Replacement (TAVR) trials, including comparisons, study stages, and newer devices. It covers different trial populations, primary and secondary endpoints, and the evaluation of non-inferiority. Su

0 views • 18 slides

Investigating the long-term effects of two transcatheter aortic valve systems in patients with severe aortic stenosis, this study follows 739 participants over a 3-year period. The trial compares the ACURATE neo and SAPIEN 3 devices, focusing on early safety and clinical efficacy at 30 days with fol

0 views • 26 slides

In the SOLVE-TAVI trial, patients undergoing transcatheter aortic valve implantation were randomized to receive either self-expandable or balloon-expandable valves under general or local anesthesia. The study aims to compare the effectiveness and safety of different valve types and anesthesia approa

0 views • 27 slides

This study aims to evaluate the safety and efficacy of transcatheter aortic valve replacement (TAVR) in low-risk patients with bicuspid aortic valve stenosis. TAVR with Evolut valves has shown promising results in tricuspid aortic stenosis, but data on bicuspid cases are lacking. The participating s

0 views • 27 slides

Investigating reoperations after native and valve-in-valve transcatheter aortic valve replacement (TAVR), this study analyzes characteristics and implications, noting a higher frequency in valve-in-valve cases. Data on demographics and trends in reoperation rates shed light on the outcomes of these

0 views • 15 slides

The SCOPE II randomized clinical trial compared the early and mid-term performance of the ACURATE neo and CoreValve Evolut self-expanding bioprostheses for transcatheter aortic valve replacement in patients with severe aortic stenosis. The study devices differed in features such as expansion, recapt

0 views • 24 slides